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Background
T-VEC is an HSV-1-derived oncolytic immunotherapy
designed to selectively replicate within tumors, produce
GM-CSF and enhance systemic antitumor immune
responses. In OPTiM (NCT00769704), a randomized
Phase III trial of intralesional T-VEC vs subcutaneous
GM-CSF for unresected stage IIIB-IV melanoma, T-
VEC significantly improved DR rate (partial response or
complete response lasting continuously for ≥6 months;
primary endpoint) vs GM-CSF (16% vs 2%, p < 0.0001).
In the primary overall survival (OS) analysis of the ITT
population, median OS was 4.4 months longer in the T-
VEC arm than in the GM-CSF arm (23.3 months vs
18.9 months; HR = 0.79, 95%CI: 0.62-1.00; P = 0.051;
Kaufman et al. ASCO 2014; abs9008a). Here we evaluate
an association between DR and OS.
Methods
To avoid lead-time bias, OS was compared for those patients
who were alive and who achieved DR vs those who did not
at landmark times of 9, 12 and 18 months from randomiza-
tion. A Cox proportional hazards model with achievement
of DR as a time-varying indicator was also evaluated. Poten-
tial bias due to confounding was evaluated with sensitivity
analyses adjusting for prognostic factor imbalances.
Results
The analysis included all patients in the T-VEC ITT
arm (n = 295) who were alive at the 9 (n = 234), 12
(n = 209) and 18 (n = 165) month landmark times. At
9, 12 and 18 months, 20, 33 and 47 patients had a DR,
and 214, 176 and 118 did not. For patients who had a
DR vs those who did not, HRs for improved OS were
0.08 (95% CI: 0.01-0.56), 0.05 (95% CI: 0.01-0.39) and
0.13 (95% CI: 0.03-0.54) at 9, 12 and 18 months, respec-
tively, indicating that achieving a DR is associated with
improved OS. When DR was analyzed as a time-depen-
dent covariate, the HR favoured patients achieving a DR
(HR: 0.09; 95% CI: 0.03-0.29).
Conclusion
Achieving a DR was associated with marked decrease in
the risk of death (> 85% across various analyses).
Although the design of the study prevents demonstrat-
ing a causal relationship between DR and prolonged OS,
it is reasonable to assume that achieving a durable
response would lead to improvement in OS, and these
analyses support that assumption. DR should be further
explored as a surrogate for OS in patients with mela-
noma treated by immunotherapy.
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